| 6.225 -0.045 (-0.72%) | 05-29 13:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.31  |
1-year : | 10.74 |
| Resists | First : | 7.97 |
Second : | 9.19 |
| Pivot price | 6.4 |
|||
| Supports | First : | 6 | Second : | 4.99 |
| MAs | MA(5) : | 6.26 |
MA(20) : | 6.74 |
| MA(100) : | 8.92 |
MA(250) : | 11.85 |
|
| MACD | MACD : | -0.7  |
Signal : | -0.8 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 14.7 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 28.44 | Low : | 6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PAVM ] has closed above bottom band by 34.6%. Bollinger Bands are 64.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.31 - 6.34 | 6.34 - 6.37 |
| Low: | 6.04 - 6.07 | 6.07 - 6.1 |
| Close: | 6.22 - 6.27 | 6.27 - 6.32 |
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Wed, 27 May 2026
PAVM Technical Analysis & Stock Price Forecast - Intellectia AI
Tue, 19 May 2026
PAVmed Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PAVM) 2026-05-19 - Seeking Alpha
Sat, 16 May 2026
PAVmed Inc. (NASDAQ:PAVM) Q1 2026 Earnings Call Transcript - Insider Monkey
Fri, 15 May 2026
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
Fri, 15 May 2026
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Thu, 14 May 2026
First Manhattan group reports 9.6% stake in PAVmed (PAVM) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 1.67e+006 (%) |
| Held by Institutions | 42.6 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.17e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 564.7 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 82.6 % |
| Return on Equity (ttm) | -39.3 % |
| Qtrly Rev. Growth | 71000 % |
| Gross Profit (p.s.) | 656.25 |
| Sales Per Share | -50.54 |
| EBITDA (p.s.) | -229688 |
| Qtrly Earnings Growth | -5.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.13 |
| Price to Cash Flow | 0.39 |
| Dividend | 0 |
| Forward Dividend | 17720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|